Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Interleukin-2 (IL-2) Mutein Therapies Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The interleukin-2 (il-2) mutein therapies market size has seen rapid expansion in recent years. It is projected to increase from $0.73 billion in 2025 to $0.84 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.1%. The historical growth in this market can be attributed to advancements in cytokine engineering techniques, a greater understanding of immune signaling pathways, early clinical success of modified IL-2 therapies, growing investment in immuno-oncology research, and the rising prevalence of immune-mediated diseases.
The interleukin-2 (il-2) mutein therapies market is anticipated to experience substantial expansion in the coming years. Its valuation is projected to reach $1.43 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.4%. This growth during the projection period stems from factors such as the broader adoption of personalized immunotherapy methods, heightened clinical trial engagement for advanced cytokines, a surging need for more secure immune modulators, enhanced regulatory backing for novel biologics, and a rise in collaborations between biotechnology and pharmaceutical firms. Key developments expected within this period involve the intensified creation of receptor-biased il-2 muteins, a greater emphasis on mitigating cytokine toxicity, wider application of combined immunotherapy protocols, the extension of precision immune modulation strategies, and augmented clinical pipeline work for autoimmune and oncology conditions.
Get A Free Sample Report With In-Depth Market Insights:
Interleukin-2 (IL-2) Mutein Therapies Market Growth Catalysts And Demand Drivers
The interleukin-2 (IL-2) mutein therapies market is anticipated to expand due to the escalating need for targeted immunotherapies. These treatments are specifically engineered to modulate the immune system, enabling it to selectively target cancer cells while minimizing harm to healthy tissues. The growing requirement for these therapies stems from healthcare providers and researchers seeking safer and more effective alternatives to conventional chemotherapy and radiation therapy, both of which are frequently associated with significant toxicity and limited specificity. IL-2 mutein therapies advance targeted immunotherapies by utilizing engineered variants of interleukin-2 that selectively stimulate immune effector cells crucial for anti-tumor responses, concurrently reducing the activation of pathways linked to systemic toxicity. For example, in April 2025, as reported by the Cancer Research Institute, a US-based non-profit organization, the FDA granted approvals for 17 new targeted immunotherapy agents in 2024. This development broadened the options available for immune-based cancer treatment and increased the patient population eligible to benefit from such therapies. Consequently, the increasing demand for targeted immunotherapies is fueling the expansion of the interleukin-2 (IL-2) mutein therapies market.
Interleukin-2 (IL-2) Mutein Therapies Market Segment Performance And Emerging Opportunities
The interleukin-2 (il-2) mutein therapies market covered in this report is segmented –
1) By Product Type: Monotherapy; Combination Therapy
2) By Route Of Administration: Intravenous; Subcutaneous; Other Route Of Administrations
3) By Application: Cancer; Autoimmune Diseases; Infectious Diseases; Other Applications
4) By End User: Hospitals; Specialty Clinics; Research Institutes; Other End Users
Subsegments:
1) By Monotherapy: Single Agent Interleukin Two Mutein Therapy; Standalone Cytokine Based Immunotherapy; Targeted Immune Modulation Therapy
2) By Combination Therapy: Interleukin Two Mutein With Immune Checkpoint Inhibitors; Interleukin Two Mutein With Chemotherapy; Interleukin Two Mutein With Targeted Biologic Therapies; Interleukin Two Mutein With Cell Based Therapies
Interleukin-2 (IL-2) Mutein Therapies Market Trends Shaping Long-Term Demand
Companies operating in the interleukin-2 (IL-2) mutein therapies market are increasingly concentrating on technological advancements within cytokine-based immunotherapy, specifically concerning selective regulatory T-cell (Treg) activation through engineered IL-2 muteins. This process of selective regulatory T-cell activation via engineered IL-2 muteins utilizes genetically modified IL-2 proteins crafted to primarily stimulate Tregs while restricting the activation of effector immune cells. For example, in December 2023, Almirall S.A., a Spain-based pharmaceutical company, initiated the first Phase I clinical study of its engineered IL-2 mutein fusion protein, ALM223, with the goal of evaluating its safety, pharmacokinetics, immunogenicity, and pharmacodynamics in autoimmune diseases. This candidate compound features selective Treg activation, a modified Fc fusion designed to enhance molecular stability, and an engineered cytokine backbone structured to optimize immune modulation. While these technological developments highlight the promise of IL-2 muteins in achieving targeted immunomodulation and broader applicability for autoimmune conditions, their clinical efficacy and long-term safety profiles necessitate further establishment through ongoing and future trials.
Interleukin-2 (IL-2) Mutein Therapies Market Key Participants And Competitive Landscape
Major companies operating in the interleukin-2 (il-2) mutein therapies market are Merck & Co. Inc., Sanofi S.A., Roche Holding AG, Bristol-Myers Squibb, Amgen Inc., Lonza Group AG, Alkermes plc, BioNTech SE, Xencor Inc., Innovent Biologics Inc., Ascendis Pharma A/S, ShanghAI Junshi Biosciences Co. Ltd., Mural Oncology Inc., ProBioGen AG, Werewolf Therapeutics Ltd., Philogen S.p.A., Cue Biopharma Inc., Medicenna Therapeutics Corp., Bright Peak Therapeutics Inc., Iovance Biotherapeutics Inc.
View The Full Interleukin-2 (IL-2) Mutein Therapies Market Report:
Interleukin-2 (IL-2) Mutein Therapies Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the interleukin 2 (IL-2) mutein therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interleukin-2 (il-2) mutein therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
